Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (noted as Scinai Immunotherapeutics Ltd. in metadata) is dated October 30, 2017. The report provides an update regarding the Company's intention to delist its ordinary shares from the Tel Aviv Stock Exchange (TASE).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate action update rather than a financial results report.
Material Changes
The primary material change is the scheduled delisting of the Company's ordinary shares from the TASE. The last trading date on the TASE is set for January 18, 2018, with the official delisting date on January 22, 2018. The Company's American Depositary Shares (ADSs) will continue to trade on the Nasdaq Capital Market.
Guidance, Outlook, and Management Commentary
- Share Conversion: Shareholders holding shares on the TASE are urged to convert them to ADSs to continue trading on Nasdaq. The conversion ratio is 40 Shares to 1 ADS.
- Costs: The Company will bear the costs and commissions associated with the conversion of Shares to ADSs charged by banks and brokers until the Delisting Date.
- Risks/Contingencies: The filing does not explicitly detail new risks or contingencies beyond the operational transition of the delisting process.
Important Facts for Investors to Verify
- Confirm the last trading date on the TASE (January 18, 2018) to avoid holding shares on a delisted exchange.
- Verify the conversion ratio of 40 Shares to 1 ADS with your broker.
- Ensure your broker is aware of the conversion request to maintain liquidity on the Nasdaq.
- Confirm that the Company is covering conversion fees as stated in the filing.